Covid 19 Clinical Trials

	Name (Synonyms)	Correlation
drug1145	The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki	1.00
drug170	Blood collection on admission and longitudinally Wiki	1.00

Correlated MeSH Terms (13)

	Name (Synonyms)	Correlation
D001997	Bronchopulmonary Dysplasia NIH	1.00
D008595	Menorrhagia NIH	1.00
D006470	Hemorrhage NIH	1.00
D006929	Hyperaldosteronism NIH	1.00
D014552	Urinary Tract Infections NIH	1.00
D000309	Adrenal Insufficiency NIH	1.00
D054559	Hyperphosphatemia NIH	1.00
D007008	Hypokalemia NIH	1.00
D006973	Hypertension NIH	0.38
D003141	Communicable Diseases NIH	0.11
D007239	Infection NIH	0.07
D045169	Severe Acute Respiratory Syndrome NIH	0.06
D018352	Coronavirus Infections NIH	0.05

Correlated HPO Terms (6)

	Name (Synonyms)	Correlation
HP:0000132	Menorrhagia HPO	1.00
HP:0002905	Hyperphosphatemia HPO	1.00
HP:0002900	Hypokalemia HPO	1.00
HP:0000846	Adrenal insufficiency HPO	1.00
HP:0000859	Hyperaldosteronism HPO	1.00
HP:0000822	Hypertension HPO	0.38

There is one clinical trial.

Clinical Trials

1 Identification of Predictive Immune Biomarkers Based on the Understanding of COVID-19 Pathogenesis to Influence Therapeutic Management

The spectrum of the COVID-19 disease ranges from benign to asymptomatic to viral pneumopathy that can progress to acute respiratory distress syndrome (ARDS). The host-pathogen relationships and the physiopathological mechanisms underlying the clinical aggravation of COVID-19 patients remain misunderstood. The project aim is to create a prospective cohort of biological samples collected from well characterized COVID-19 patients. This project aims first to identify based on these samples an early immune signature predictive of clinical worsening of COVID-19 patients in order to improve their management, and secondarily to better understand pathophysiological mechanisms underlying the different phases of the disease in order to identify innovative therapeutic targets and vaccine perspectives.

NCT04385108 COVID-19 Biological: Blood collection on admission and longitudinally Biological: Blood collection on their first consultation and 10 to 14 days later

Primary Outcomes

Description: Analysis of the phenotypic profiling of blood T-cells by multicolor fluorescence-activated cell sorter (FACS) analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers

Measure: Immune signature

Time: Day 0

Description: Analysis on plasma samples of a wide range of cytokines and chemokines using multiplex

Measure: Dosage of cytokines and chemokines in plasma samples

Time: Day 0

Secondary Outcomes

Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers

Measure: Immune signature

Time: Day 2

Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers

Measure: Immune signature

Time: Day 4

Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers

Measure: Immune signature

Time: Day 8

Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers

Measure: Immune signature

Time: Day 12

Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers

Measure: Immune signature

Time: Day 30 (or in discharge)

Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin